logo-loader

Redx Pharma chief "encouraged" by latest data on fibrosis drug candidate

Published: 12:00 13 Feb 2019 GMT

Redx Pharma Plc’s (LON:REDX) chief executive Lisa Anson tells Proactive London how “encouraged” she and the company is about the latest pre-clinical data from a fibrosis drug set to enter human trials next year.News here too on what this means for the company and indeed fibrosis sufferers themselves.The lab tests showed the Redx drug was able to suppress collagen deposition and pathways associated with fibrosis, meaning it could have an impact on established forms of the disease.
Its profile suggests the putative treatment is suitable to be taken by mouth, rather than injected directly into the blood system.
Three independent studies assessed the potential efficacy of the company’s lead ROCK2 compound in animal models of lung, kidney and liver fibrosis.

Redx Pharma achieves milestone with dosing of first participant in Phase 1...

  Redx Pharma PLC (AIM:REDX) CEO Lisa Anson discusses the enrollment of the first participant in its RXC008 Phase 1 clinical trial in an interview with Proactive's Stephen Gunnion. RXC008 is a 'first-in-class' ROCK inhibitor, designed to be gut-restricted, targeting fibrostenotic Crohn's...

2 weeks, 6 days ago